Abstract
The early growth response-1 (Egr-1) gene encodes a Cys2-His2-type zinc-finger transcription factor. A broad range of extra cellular stimuli are known to lead to its induction thus furthering growth, proliferation, differentiation or apoptosis. Accordingly, Egr-1 is involved in a variety of diseases such as atherosclerosis or cancer. Among other functional elements, five serum response elements (SRE) have been identified in the promoter region of Egr-1. The Rho/Rho-kinase pathway has been shown to regulate actin reorganization via LIM-kinase mediated cofilin phosphorylation. Recent studies revealed the actin binding striated muscle activator of Rho signaling (STARS) to promote translocation of myosin related transcription factors (MRTFs) into the nucleus leading to serum response factor (SRF) activation. The ternary complex factor (TCF) Elk-1 eventually bridges the gap between SRF mediated gene transcription and the Raf/MEK/ERK pathway. Furthermore, the Egr-1 promoter has two cAMP response elements (CREs), whose relevance for gene expression is still controversial. An Egr-1 binding site (EBS) is located on the Egr-1 promoter itself arguing for a negative feedback mechanism. The acquired knowledge on transcriptional regulation, however, is not entirely understood. In this review we highlight upstream and downstream signaling in vitro and in vivo associated with Egr-1.
Keywords: Egr-1, signal transduction cascades, serum response factor, Rho-kinase, ERK1/2
Current Signal Transduction Therapy
Title: Concepts of Egr-1 Activation – A Hub for Signal Transduction Cascades
Volume: 5 Issue: 2
Author(s): Judith-Irina Pagel and Elisabeth Deindl
Affiliation:
Keywords: Egr-1, signal transduction cascades, serum response factor, Rho-kinase, ERK1/2
Abstract: The early growth response-1 (Egr-1) gene encodes a Cys2-His2-type zinc-finger transcription factor. A broad range of extra cellular stimuli are known to lead to its induction thus furthering growth, proliferation, differentiation or apoptosis. Accordingly, Egr-1 is involved in a variety of diseases such as atherosclerosis or cancer. Among other functional elements, five serum response elements (SRE) have been identified in the promoter region of Egr-1. The Rho/Rho-kinase pathway has been shown to regulate actin reorganization via LIM-kinase mediated cofilin phosphorylation. Recent studies revealed the actin binding striated muscle activator of Rho signaling (STARS) to promote translocation of myosin related transcription factors (MRTFs) into the nucleus leading to serum response factor (SRF) activation. The ternary complex factor (TCF) Elk-1 eventually bridges the gap between SRF mediated gene transcription and the Raf/MEK/ERK pathway. Furthermore, the Egr-1 promoter has two cAMP response elements (CREs), whose relevance for gene expression is still controversial. An Egr-1 binding site (EBS) is located on the Egr-1 promoter itself arguing for a negative feedback mechanism. The acquired knowledge on transcriptional regulation, however, is not entirely understood. In this review we highlight upstream and downstream signaling in vitro and in vivo associated with Egr-1.
Export Options
About this article
Cite this article as:
Pagel Judith-Irina and Deindl Elisabeth, Concepts of Egr-1 Activation – A Hub for Signal Transduction Cascades, Current Signal Transduction Therapy 2010; 5 (2) . https://dx.doi.org/10.2174/157436210791112190
DOI https://dx.doi.org/10.2174/157436210791112190 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NMR in Metabolic Profiles of Neural Stem/Progenitor Cells: Current Status and Relevant Problems
Current Medical Imaging Multifunctional Nanoparticles, Nanocages and Degradable Polymers as a Potential Novel Generation of Non-Invasive Molecular and Cellular Imaging Systems
Recent Patents on Nanotechnology Endocannabinoid Signaling in Midbrain Dopamine Neurons: More than Physiology?
Current Neuropharmacology The TWEAK-Fn14 System: Breaking the Silence of Cytokine-Induced Skeletal Muscle Wasting
Current Molecular Medicine The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells
Current Medicinal Chemistry - Anti-Cancer Agents Patent Selections
Recent Patents on DNA & Gene Sequences Tissue Biomarkers for Prostate Cancer Radiation Therapy
Current Molecular Medicine Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Natural Sirtuin Modulators in Drug Discovery: A Review (2010 -2020)
Current Medicinal Chemistry Targeting the Endocannabinoid System for the Treatment of Cancer – A Practical View
Current Topics in Medicinal Chemistry Alkaloids from Cyanobacteria with Diverse Powerful Bioactivities
Mini-Reviews in Medicinal Chemistry NGR-based Strategies for Targeting Delivery of Chemotherapeutics to Tumor Vasculature
Anti-Cancer Agents in Medicinal Chemistry Prognostic Value and Clinicopathological Differences of Bmi1 in Gastric Cancer: A Meta-analysis
Anti-Cancer Agents in Medicinal Chemistry Cordycepin in Anticancer Research: Molecular Mechanism of Therapeutic Effects
Current Medicinal Chemistry A Key Role for Connexin Hemichannels in Spreading Ischemic Brain Injury
Current Drug Targets Hepatocellular Carcinoma: Important Biomarkers and their Significance in Molecular Diagnostics and Therapy
Current Medicinal Chemistry Second Generation Taxanes: from the Natural Framework to the Challenge of Drug Resistance
Current Medicinal Chemistry - Anti-Cancer Agents Targeting Apoptotic Signaling Pathways in Human Lung Cancer
Current Cancer Drug Targets Applications of Nanosystems to Anticancer Drug Therapy (Part I. Nanogels, Nanospheres, Nanocapsules)
Recent Patents on Anti-Cancer Drug Discovery A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry